Alnylam Pharmaceuticals Surges to Top 257 Most Actively Traded Stocks with $395 Million in Volume Following FDA Approval of Patisiran

On July 16, 2025, Alnylam Pharmaceuticals (ALNY) saw a significant surge in trading volume, reaching $395 million, marking a 36.62% increase from the previous day. This surge placed Alnylam among the top 257 most actively traded stocks for the day.

Alnylam Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has approved its investigational drug, patisiran, for the treatment of hereditary transthyretin amyloidosis (hATTR). This approval is a major milestone for the company, as it represents the first RNA interference (RNAi) therapeutic to receive FDA approval. The drug is designed to reduce the production of transthyretin protein, which is responsible for the formation of amyloid deposits in the body, leading to hATTR.

In addition to the FDA approval, Alnylam has also reported positive results from its Phase 3 clinical trial for inotersen, another investigational drug for the treatment of hATTR. The trial demonstrated a significant reduction in the progression of neuropathy and improved quality of life for patients. These results further solidify Alnylam's position as a leader in the development of RNAi therapeutics for rare genetic diseases.

Furthermore, Alnylam has announced a strategic partnership with a leading biopharmaceutical company to co-develop and commercialize a new class of RNAi therapeutics for the treatment of cardiovascular diseases. This partnership is expected to accelerate the development of new treatments and expand Alnylam's pipeline of innovative therapies.